As already acknowledged, one of the hallmarks of GCTs is the presence of wild-type (WT) tp53 in most patients, although mutations in tp53 have been described in a few cases in the past [43] and more recently in a small subset (~7–15%) of cisplatin-resistant or relapsed GCT patients [34,44]. This evidence concerns the gene TP53 and granular cell tumor.